IN.PACT AV drug-coated balloon is first and only to show superior and sustained results through two years compared to PTA in treating arteriovenous fistulae lesions.

Medtronic plc announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study . The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity. "A patient who receives hemodialysis will often need to have several reinterventions each year to maintain patency and keep critical access sites open and functioning properly," said Andrew Holden, MBChB, FRANZCR, director of interventional radiology at Auckland Hospital and associate professor of radiology at Auckland University. "Being able to show these results at two years will ultimately impact standard of care for patients undergoing dialysis. For my patients, these durable results translate into fewer reinterventions and a better quality of life." AV fistulae are created and used to deliver hemodialysis to patients with ESRD. Over time, vessel restenosis limits the ability to use AV fistulae effectively. In order to restore function, patients often undergo one to three AV fistula maintenance procedures per year. The need for frequent reinterventions can result in significant disruptions to critical hemodialysis care and increased costs to the healthcare system. Drug-coated balloons have the potential to extend the time between reinterventions by maintaining AV access site patency, therefore maximizing a patient's uninterrupted access to lifesaving dialysis care. Over two years, the IN.PACT AV DCB group demonstrated a continued clinical benefit compared to the PTA control group. Key data highlights per Kaplan-Meier estimates for this dataset include : i. Target lesion primary patency through 24 months was 52.2% in the IN.PACT AV DCB group compared to 36.2% in the PTA control group (log-rank p<0.001). ii. access circuit primary patency through 24 months was 39.5% in the in.pact av dcb group compared to 25.4% in the pta control group (log-rank p><0.001). iii. freedom from all-cause mortality through 24 months was 82.4% in the in.pact av dcb study group and 82.8% in the pta control group (log-rank p="0.829)." about the in.pact av access study : the in.pact av access study is a prospective, global, single-blinded, randomized controlled trial (rct), which enrolled 330 subjects at 29 sites in the united states, japan and new zealand. results of the six-month pivotal in.pact av access study were presented at cirse in september 2019 and also published in the new england journal of medicine in august 2020.>